Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of FWD1802 monotherapy in ER-positive/HER2-negative unresectable locally advanced or metastatic breast cancer
CTR20232130Phase 2Active
- Sponsor
- Forward Pharma
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fwd1802 in breast cancer, sponsored by Forward Pharma. Started Sep 2023; status: active.
02
Drugs
fwd1802
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232130.